Induction of immune responses and safety profiles in rhesus macaques immunized with a DNA vaccine expressing human prostate specific antigen
- PMID: 11494145
- DOI: 10.1038/sj.onc.1204542
Induction of immune responses and safety profiles in rhesus macaques immunized with a DNA vaccine expressing human prostate specific antigen
Abstract
Prostate specific antigen (PSA) is a widely used marker for prostate cancer, which is secreted by normal prostate cells at low levels, but is produced more substantially by cancer cells. We have previously reported on the use of a DNA vaccine construct that encodes for human PSA gene to elicit host immune responses against cells producing PSA. DNA immunization strategy delivers DNA constructs encoding for a specific immunogen into the host, who becomes the in vivo protein source for the production of antigen. This antigen then is the focus of the resulting immune response. In this study, we examine the induction of immune responses and safety profiles in rhesus macaques immunized with DNA-based PSA vaccine. We observed induction of PSA-specific humoral response as well as positive PSA-specific lymphoproliferative (LPA) response in the vaccinated macaques. We also observed that the stimulated T cells from the PSA-immunized rhesus macaques produced higher levels of Th1 type cytokine IFN-gamma than the control vector immunized animals. On the other hand, DNA immunization did not result in any adverse effects in the immunized macaques, as indicated by complete blood counts, leukocyte differentials and hepatic and renal chemistries. The macaques appeared healthy, without any physical signs of toxicity throughout the observation period. In addition, we did not observe any adverse effect on the vaccination site. The apparent safety and immunogenecity of DNA immunization in this study suggest that further evaluation of this vaccination strategy is warranted.
Similar articles
-
Engineering enhancement of immune responses to DNA-based vaccines in a prostate cancer model in rhesus macaques through the use of cytokine gene adjuvants.Clin Cancer Res. 2001 Mar;7(3 Suppl):882s-889s. Clin Cancer Res. 2001. PMID: 11300487
-
Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine.Oncogene. 1998 Dec 17;17(24):3125-35. doi: 10.1038/sj.onc.1201736. Oncogene. 1998. PMID: 9872328
-
Immunogenicity and safety of a recombinant vaccinia virus vaccine expressing the carcinoembryonic antigen gene in a nonhuman primate.Cancer Res. 1992 Dec 15;52(24):6917-25. Cancer Res. 1992. PMID: 1458480
-
[Novel vaccines against M. tuberculosis].Kekkaku. 2006 Dec;81(12):745-51. Kekkaku. 2006. PMID: 17240920 Review. Japanese.
-
CpG oligonucleotide as an adjuvant for the treatment of prostate cancer.Adv Drug Deliv Rev. 2009 Mar 28;61(3):268-74. doi: 10.1016/j.addr.2008.12.005. Epub 2009 Jan 7. Adv Drug Deliv Rev. 2009. PMID: 19166887 Review.
Cited by
-
A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer.Br J Cancer. 2004 Aug 16;91(4):688-94. doi: 10.1038/sj.bjc.6602019. Br J Cancer. 2004. PMID: 15280930 Free PMC article. Clinical Trial.
-
Human T lymphocyte responses against lung cancer induced by recombinant truncated mouse EGFR.Cancer Immunol Immunother. 2006 Apr;55(4):386-93. doi: 10.1007/s00262-005-0028-3. Epub 2005 Oct 19. Cancer Immunol Immunother. 2006. PMID: 16235052 Free PMC article.
-
Optimised electroporation mediated DNA vaccination for treatment of prostate cancer.Genet Vaccines Ther. 2010 Feb 5;8(1):1. doi: 10.1186/1479-0556-8-1. Genet Vaccines Ther. 2010. PMID: 20181099 Free PMC article.
-
Genetic vaccination with Flt3-L and GM-CSF as adjuvants: Enhancement of cellular and humoral immune responses that results in protective immunity in a murine model of hepatitis C virus infection.World J Gastroenterol. 2006 Nov 28;12(44):7118-25. doi: 10.3748/wjg.v12.i44.7118. World J Gastroenterol. 2006. PMID: 17131473 Free PMC article.
-
Advances in prostate cancer immunotherapies.Drugs Aging. 2007;24(3):197-221. doi: 10.2165/00002512-200724030-00003. Drugs Aging. 2007. PMID: 17362049 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous